Reduced Brain Cannabinoid Receptor Availability in Schizophrenia

Abstract

BACKGROUND Several lines of evidence suggest the presence of abnormalities in the endocannabinoid (eCB) system in schizophrenia (SCZ). However, there are limited in vivo measures of the eCB system in SCZ. METHODS Twenty five male SCZ subjects (SCZs), 18 antipsychotic treated [SCZ-MED] and 7 antipsychotic free [SCZ-UNMED]) were compared to 18 age- matched male healthy control subjects (HCs). Subjects underwent one Positron Emission Tomography (PET) scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [11C]OMAR on the High Resolution Research Tomography (HRRT) scanner. Regional volume of distribution (VT) values were determined using kinetic modeling of PET data as a measure of CB1R availability. Group differences in mean composite [11C]OMAR VT values were compared between SCZs and HCs. Exploratory comparisons of CB1R availability within 15 brain regions were also conducted. All analyses were covaried for age and body mass index. RESULTS SCZs showed significantly (p =0.02) lower composite [11C]OMAR VT relative to HCs (~12% difference, effect size d= 0.73). [11C]OMAR VT was significantly (all ps <0.05) lower in SCZs in the amygdala, caudate, posterior cingulate cortex, hippocampus, hypothalamus and insula. Composite [11C]OMAR VT was greater in HCs> SCZ-MED>SCZ-UNMED. Furthermore, composite [11C]OMAR VT was greater in HCs> SCZ smokers (n=11) > SCZ non-smokers (n=14). CONCLUSIONS CB1R availability is lower in males SCZs compared to HCs. Furthermore, antipsychotics and tobacco use may increase CB1R availability in this population. The findings of the study provide further evidence supporting the hypothesis that alterations in the eCB system might contribute to the pathophysiology of SCZ.

Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks

“…Several post-mortem studies demonstrate that individuals with schizophrenia have highly abnormal CB 1 receptor expression patterns in the PFC (Dalton et al, 2011; Dean et al, 2001; Eggan et al, 2010; Volk et al, 2014). Furthermore, neuroimaging evidence suggests there are widespread alterations in CB 1 receptor levels in patients with schizophrenia (Ceccarini et al, 2013; Ranganathan et al, 2016; Wong et al, 2010), including significantly reduced levels in the hippocampus (Ranganathan et al, 2016). While PFC dysfunction is primarily thought to underlie cognitive deficits, hippocampal dysfunction is associated with both positive and negative (e.g.…”

Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis

“…In the CNS, the CB1R plays an important role in cognition 22 and has been implicated in mood and anxiety disorders 23,24 . Recent evidence from both our group and others suggests that central CB1R availability is altered psychosis [25][26][27] . We recently showed that CB1R availability is altered in patients with psychosis, where greater reductions in CB1R levels are associated with greater symptom severity and poorer cognitive functioning 27 .…”

Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains

“…A postmortem study corroborated this finding . In contrast, another PET investigation reported a decrease in CB1 binding in schizophrenic patients compared to controls . These divergent findings might be related to the gender, sex, and age of the subjects, the different affinity and pharmacokinetics of PET traces, the disease duration, and the substance abuse .…”